Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ

21.78

-1.07(-4.68%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Emil D. Kakkis	Founder, President, Chief Executive Officer & Director	1.19M	1960
Dennis Karl Huang	Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations	331,330	1965
Eric Olson	Chief Business Officer & Executive Vice President	714,838	N/A
Karah Herdman Parschauer	Chief Legal Officer & Executive Vice President of Corporate Affairs	819,872	1978
Howard Horn	Executive Vice President of Corporate Strategy & Chief Financial Officer	846,010	1979
Eric Crombez	Chief Medical Officer & Executive Vice President	882,356	1973
John Richard Pinion	Chief Quality Operations Officer & Executive Vice President of Translational Sciences	923,934	1966
Erik Harris	Executive Vice President & Chief Commercial Officer	925,255	1970
Ernie W. Meyer	Chief Human Resources Officer & Executive Vice President	0	1965
Paul Wickman	Vice President of Intellectual Property	0	N/A
Aaron Olsen	Senior Vice President of Corporate Strategy & Finance	0	N/A
Arjun Natesan	Vice President of Translational Research	0	N/A
Alison Skrinar	Vice President of Clinical Outcomes Research and Evaluation	0	1970
Theodore A. Huizenga	Senior Vice President, Corporate Controller & Principal Accounting Officer	0	1971
Vimal Srivastava	Senior Vice President of Business Development & Alliance Management	0	1965

Name

Title

Pay

Year Born

Emil D. Kakkis

Founder, President, Chief Executive Officer & Director

1.19M

1960

Dennis Karl Huang

Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations

331,330

1965

Eric Olson

Chief Business Officer & Executive Vice President

714,838

N/A

Karah Herdman Parschauer

Chief Legal Officer & Executive Vice President of Corporate Affairs

819,872

1978

Howard Horn

Executive Vice President of Corporate Strategy & Chief Financial Officer

846,010

1979

Eric Crombez

Chief Medical Officer & Executive Vice President

882,356

1973

John Richard Pinion

Chief Quality Operations Officer & Executive Vice President of Translational Sciences

923,934

1966

Erik Harris

Executive Vice President & Chief Commercial Officer

925,255

1970

Ernie W. Meyer

Chief Human Resources Officer & Executive Vice President

1965

Paul Wickman

Vice President of Intellectual Property

N/A

Aaron Olsen

Senior Vice President of Corporate Strategy & Finance

N/A

Arjun Natesan

Vice President of Translational Research

N/A

Alison Skrinar

Vice President of Clinical Outcomes Research and Evaluation

1970

Theodore A. Huizenga

Senior Vice President, Corporate Controller & Principal Accounting Officer

1971

Vimal Srivastava

Senior Vice President of Business Development & Alliance Management

1965

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.